P21 Price Comparison

Live prices from 2 SA suppliers, from R570.00, compared side by side so you never overpay.

Neuropeptides & sleep research Prices checked
We compare prices & may earn a commission. We do not sell or supply any products. Full disclosure.

We may earn a commission from the suppliers listed here. Read our full disclosure.

Best Price R750.00
Average R750.00
Highest R750.00
1 result
Best Price
Crono Pharm logo

P21

In Stock 5mg Lab Tested
R750.00
+ R150.00 delivery

Compare another peptide

PeptideSupermarket® compares prices but doesn't sell products.

All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.

We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.

By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.

P21 Profile

Emerging

P021 | CNTF-Derived Neurogenic Peptide

Overview

P21 is a nootropic peptide derived from ciliary neurotrophic factor (CNTF) that enhances neurogenesis and cognitive function. It contains an adamantane moiety that enables blood-brain barrier penetration. Research shows it increases BDNF expression, inhibits LIF signaling to promote neurogenesis, and reduces tau and amyloid pathology in Alzheimer's disease models. Remarkably, P21 can boost neurogenesis in diseased brains above levels seen in healthy untreated brains.

Mechanism of Action

P21 operates through multiple pathways: it inhibits leukemia inhibitory factor (LIF) signaling, removing a key roadblock to neurogenesis and shifting the brain toward a more embryologic state favoring neuron growth. It increases brain-derived neurotrophic factor (BDNF) expression and activates the BDNF/TrkB/PI3-K/AKT/GSK3β pathway. This pathway modulation improves cognitive function and reduces tau and amyloid pathologies.

Key Benefits

  • Potent promotion of neurogenesis in the dentate gyrus
  • Increased BDNF expression
  • Reduced tau protein pathology
  • Reduced amyloid-beta plaque formation
  • Improved cognitive function and memory
  • Restored synaptic deficits in cortex and hippocampus
  • Reduced mortality rate in AD models
  • Crosses blood-brain barrier effectively

Quick Stats

Typical Dose
Research compound - dosing not established for humans
Frequency
Daily in animal research protocols
Cycle Duration
Not established - experimental peptide without human trials
Storage
Refrigerate at 2-8°C

Molecular Information

Molecular Weight
~1,100 Da
Type
CNTF-derived peptide
Half-Life
Over 3 hours (mouse plasma)

Modifications

Contains adamantane for BBB penetration

Research Indications

The following information is derived from published scientific literature and is provided for educational and research reference purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. These peptides are not approved for human use and are sold exclusively for in-vitro laboratory research.

Alzheimer's Disease

Effective

P021 markedly reduced tau pathology, attenuated Aβ generation, and rescued episodic memory impairment in 3xTg-AD mice.

Neurodegeneration Prevention

Effective

Treatment during synaptic compensation period can prevent neurodegeneration and reduce mortality.

Tau Pathology

Effective

Robust attenuation of tau pathologies through BDNF/TrkB/PI3-K/AKT/GSK3β pathway.

Neurogenesis

Most Effective

Enhances dentate gyrus neurogenesis so effectively it exceeds levels in healthy untreated brains.

Memory Processes

Effective

Enhances memory processes through increased BDNF and restored synaptic function.

Age-Related Cognitive Decline

Moderate

May reduce natural decline in learning and memory in aged models by rescuing neurogenesis deficit.

Synaptic Plasticity

Effective

Restores synaptic deficits in cortex and hippocampus.

Neuronal Plasticity

Effective

Rescues deficits in neuronal plasticity.

Dosing Protocols

injectable

P21 has not yet been tested in human clinical trials. Research protocols in animal models use subcutaneous or intraperitoneal injection. The adamantane moiety enables blood-brain barrier penetration for CNS effects.

Goal Dose Frequency Route
Research protocol Variable by study Daily SubQ or IP

Key Tips

  • Adamantane enables BBB penetration
  • Promising preclinical results
  • Oral availability being researched
Materials Needed
Bacteriostatic water (BAC) Insulin syringes Alcohol swabs Peptide vial Sterile work surface
Steps
  1. 1 Clean work area and hands thoroughly
  2. 2 Calculate required BAC water volume
  3. 3 Draw BAC water into syringe
  4. 4 Inject slowly down vial side
  5. 5 Gently swirl until dissolved (never shake)
  6. 6 Store in refrigerator

Peptide Interactions

Semax

Compatible

Different nootropic mechanisms; may complement each other.

Dihexa

Compatible

Both promote neurogenesis through different pathways.

BPC-157

Compatible

No known negative interactions; different mechanisms.

NA-Semax Amidate

Compatible

Different cognitive enhancement mechanisms.

What to Expect

Days-Weeks

BDNF elevation begins

Weeks

Neurogenesis enhancement measurable

Weeks-Months

Cognitive improvements in research models

Long-term

Disease-modifying effects in AD models

Side Effects & Safety

Common Side Effects

  • Limited data - primarily preclinical research
  • Generally well-tolerated in animal studies

Monitoring

  • Experimental peptide - medical supervision essential
  • No human clinical trials completed

Stop Signs

  • Allergic reactions
  • Unusual neurological symptoms

Contraindications

  • Not approved for human use
  • Pregnancy or breastfeeding
  • Unknown safety profile in humans

Quality Checklist

Good Signs

  • White lyophilized powder
  • Clear solution after reconstitution
  • High purity (>95%)
  • Intact vacuum seal

Warning Signs

  • Research chemical - limited quality standards

Bad Signs

  • Discoloration
  • Cloudy solution
  • Particulates visible

Research & References

Key References

  1. 2018

    P021 Treatment in 3xTg-AD Mice

    Journal of Alzheimer's Disease

    P021 markedly reduced tau pathology, attenuated Aβ, rescued episodic memory, and reduced mortality in AD mice.

  2. 2019

    P21 and BDNF/TrkB Pathway

    Neuropharmacology

    Disease-modifying effect via BDNF/TrkB/PI3-K/AKT/GSK3β pathway; rescued neurogenesis and cognition.

  3. 2017

    P21 in Cognitive Aging

    Neurobiology of Aging

    May reduce age-related cognitive decline by restoring BDNF expression and synaptic function.

  4. 2020

    P21 as Promising AD Drug Candidate

    Alzheimer's Research & Therapy

    Beneficial effects in preclinical studies make P21 highly promising for AD drug development.

Search PubMed for P21

Get Peptide Price-drop Alerts

Be the first to know when prices drop on your favourite peptides

No spam. Unsubscribe anytime. We respect your privacy.